Delayed US filing for vortioxetine the first under Lundbeck/Takeda alliance
This article was originally published in Scrip
Executive Summary
Lundbeck and Takeda have made the first filing under their 2007 alliance for the joint development and commercialisation of Lundbeck pipeline compounds for mood and anxiety disorders, applying for the US approval of vortioxetine (Lu AA21004) for major depressive disorder in adults.